Form 4: Viking Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Greg Zante, Chief Financial Officer of Viking Therapeutics, Inc., sold 21,217 shares of common stock on July 28, 2026 for $33.47 per share.
Summary
- Grant/award: acquired 31,667 Common Stock, par value $0.00001 per share on July 28, 2026; holds 233,421 after (Direct).
- Open-market sale: disposed of 21,217 Common Stock, par value $0.00001 per share at $33.47 ($710,141) on July 29, 2026; holds 212,204 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $710,141 of stock on the open market.
Insider Transactions
Greg Zante — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-28 | Grant/award | Common Stock, par value $0.00001 per share | 31,667 | — | — | 233,421 |
| 2026-07-29 | Open-market sale | Common Stock, par value $0.00001 per share | 21,217 | $33 | $710.1K | 212,204 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-28 | Grant/award (31,667 shares) |
| 2026-07-29 | Open-market sale (21,217 shares) |
Keywords
insider transaction, Form 4, VKTX, Viking Therapeutics, Inc., bearish, Greg Zante
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.